| Literature DB >> 33717082 |
Grace Thompson1, Andrew McLean-Tooke1, Michaela Lucas1,2.
Abstract
Current understanding of cross-reactivity in severe cutaneous adverse reactions to beta-lactam antibiotics is limited, thereby making recommendations for future prescribing difficult. The underlying immunopathogenesis of these reactions is not completely understood but involves interactions between small molecule drugs, T cells and HLA molecules. Historically, these reactions were considered to be specific to the inciting antibiotic and therefore likely to have minimal cross-reactivity. We assessed patients presenting with non-SJS/TEN severe cutaneous adverse reactions to a tertiary hospital drug allergy clinic. In our case series cross-reactivity or co-reactivity commonly occurred among the beta-lactam antibiotic class, however further research is required to investigate and understand patterns of cross-reactivity. Based on our experience we provide clinicians with a practical algorithm for testing for cross-reactivity in non-SJS/TEN severe cutaneous adverse reactions.Entities:
Keywords: antibiotic co-reactivity; antibiotic cross-reactivity; antibiotics; beta-lactam; severe cutaneous adverse drug reactions
Year: 2021 PMID: 33717082 PMCID: PMC7947317 DOI: 10.3389/fimmu.2021.601954
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561